Novo Nordisk: shares rise after Tresiba label update
(CercleFinance.com) - Shares in Novo Nordisk rose on Tuesday after the FDA approved inclusion of data on cardiovascular outcomes and severe hypoglycaemia in the label for Tresiba, its type 2 diabetes treatment.
This means that Tresiba US label will now include an update to the prescribing information stating a 40% statistically significant lower rate of severe hypoglycaemia compared to insulin glargine U100, the Danish firm said.
According to analysts, the move will result in "continuous momentum over competitors".
Novo Nordisk shares are currently up 0.9% at 295.8 Danish kronor in Copenhagen.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This means that Tresiba US label will now include an update to the prescribing information stating a 40% statistically significant lower rate of severe hypoglycaemia compared to insulin glargine U100, the Danish firm said.
According to analysts, the move will result in "continuous momentum over competitors".
Novo Nordisk shares are currently up 0.9% at 295.8 Danish kronor in Copenhagen.
Copyright (c) 2018 CercleFinance.com. All rights reserved.